Peptide Knowledge Base · Longevity
Rapamycin: what it is, what the evidence says, and its real status
An mTOR-inhibiting drug, not a peptide, with the deepest lifespan-extension evidence in animal models.
Short version: not a peptide, the longevity field's most-studied mTOR inhibitor, with strong animal lifespan data and growing human interest. By request, supervised.
Can you actually get it?
Plain-English verdict: Waitlist.
Regulatory status: By request · SKU request.
By request, clinician-supervised. Rapamycin is an FDA-approved drug (for other indications) used off-label for longevity; the human longevity evidence is still emerging. It is a related longevity compound, not a peptide.
How does Rapamycin work?
An mTOR inhibitor that, intermittently dosed, is proposed to mimic some benefits of caloric restriction.
What it does — and what it does not do
What it does: Studied for longevity and immune-aging; shows lifespan extension across many animal models.
What it does not do: Human lifespan benefit is not proven, and it is not a peptide.
How honest is the evidence?
Evidence grade B — robust animal lifespan data; human longevity outcomes still emerging. Read our grading methodology for what each grade means.
What we still don't know: Optimal dose/interval for longevity in humans, and long-term immune effects, are unresolved.
WADA status: Not prohibited.
How it is taken
Clinician-set; typically intermittent oral. Educational only.
Who should not take it
Immunosuppressive; caution with infections, wound healing, and metabolic markers. Clinician-supervised.
Sources
Rapamycin / mTOR lifespan literature · ongoing human longevity trials
Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker or the knowledge base.
Last reviewed 2026-08-11 · Peptós.LIFE · Not medical advice.